Jefferies Group LLC Intellia Therapeutics, Inc. Call Options Transaction History

Jefferies Group LLC

  • $10.2 Billion
  • Q3 2022

Call Options

11 transactions
Quarter Operation Price Per call calls change calls Held SEC Form
Q1 2022

Sep 21, 2023
SELL
$58.27 - $118.99 $4.12 Million - $8.41 Million
-70,700 Reduced 77.1%
21,000 $1.53 Million
Q1 2022

May 16, 2022
SELL
$58.27 - $118.99 $4.12 Million - $8.41 Million
-70,700 Reduced 77.1%
21,000 $1.53 Million
Q3 2021

Sep 21, 2023
SELL
$132.37 - $176.78 $4.33 Million - $5.78 Million
-32,700 Reduced 26.29%
91,700 $12.3 Million
Q3 2021

Nov 15, 2021
SELL
$132.37 - $176.78 $4.33 Million - $5.78 Million
-32,700 Reduced 26.29%
91,700 $12.3 Million
Q2 2021

Sep 21, 2023
BUY
$60.88 - $161.91 $1.38 Million - $3.68 Million
22,700 Added 22.32%
124,400 $20.1 Million
Q2 2021

Aug 20, 2021
SELL
$60.88 - $161.91 $750 Million - $1.99 Billion
-12,315,600 Reduced 99.0%
124,400 $20.1 Million
Q2 2021

Aug 16, 2021
BUY
$60.88 - $161.91 $751 Million - $2 Billion
12,338,300 Added 12132.06%
12,440,000 $20.1 Million
Q1 2021

Sep 21, 2023
BUY
$46.59 - $83.68 $4.13 Million - $7.42 Million
88,700 Added 682.31%
101,700 $8.16 Million
Q1 2021

May 14, 2021
BUY
$46.59 - $83.68 $4.13 Million - $7.42 Million
88,700 Added 682.31%
101,700 $8.16 Million
Q4 2020

Sep 21, 2023
BUY
$18.83 - $63.53 $244,789 - $825,890
13,000 New
13,000 $707,000
Q3 2020

Nov 13, 2020
BUY
$17.47 - $24.93 $227,109 - $324,090
13,000 New
13,000 $258,000

Others Institutions Holding NTLA

# of Institutions
314
Shares Held
89.3M
Call Options Held
686K
Put Options Held
599K
View Full List

About Intellia Therapeutics, Inc.

NTLA Quotes by TradingView
  • Ticker NTLA
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 76,011,800
  • Market Cap $1.73B
  • Description
  • Intellia Therapeutics, Inc., a genome editing company, focuses on the development of therapeutics. The company's in vivo programs include NTLA-2001, which is in Phase 1 clinical trial for the treatment of transthyretin amyloidosis; and NTLA-2002 for the treatment of hereditary angioedema, as well as other liver-focused programs comprising hemoph...
More about NTLA
Track This Portfolio

Track Jefferies Group LLC Portfolio

Follow Jefferies Group LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Jefferies Group LLC, based on Form 13F filings with the SEC.

News

Stay updated on Jefferies Group LLC with notifications on news.

Choose your preferred platform and Sign Up 👇 Telegram Email